PRO1107 in Patients With Advanced Solid Tumors

Study summary

This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1107 (PRO1107) in participants with advanced solid tumors. This study consists of 2 parts, Part A: dose escalation and dose level expansion, and Part B: tumor specific expansion.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedGEN1107

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 1, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?7 U.S. locations

Locations may change over time.

Who runs it?Genmab

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1 / Phase 2
Sponsor: Genmab
Interventions being studied: Drug: GEN1107

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Part A:
Pathologically confirmed diagnosis of one of the following tumor types:
Ovarian cancer (epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer)
Endometrial cancer (any subtype excluding sarcoma)
Triple negative breast cancer (TNBC)
Non-small cell lung cancer (NSCLC)
Metastatic or unresectable locally advanced, recurrent, disease not amenable to further local therapy following prior systemic therapies known to confer clinical benefit. Part B:
Participants must have a histologically or cytologically confirmed metastatic or unresectable solid malignancy as specified below:
Ovarian cancer
TNBC
Endometrial cancer
NSCLC
Measurable disease at baseline as defined per RECIST, Version 1.1

Reasons someone may not be able to joinExclusion criteria

Prior treatment with anti-PTK7-directed therapy.
Had progressive disease as best response while on treatment with an auristatin (eg, a vedotin or pelidotin)- based ADC as the most recent line of therapy.
History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death (eg, 5-year overall survival \[OS\] ≥90%)
Known active central nervous system metastases, including carcinomatous meningitis. Participants with brain metastases may participate provided the metastases have been treated and are stable for at least 4 weeks prior to the first dose of study drug, they have no new or enlarging brain metastases and have discontinued corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to the first dose of study drug. Participants with a history of brain metastases, suspected new brain metastases, or a diagnosis of NSCLC or breast cancer should have a computed tomography (CT)/ magnetic resonance imaging (MRI) scan of the brain at screening.
Participants with active or chronic corneal disorders, history of corneal transplantation, or any clinically significant corneal disease that prevents adequate monitoring of potential drug-induced keratopathy. Note: Participants with other active ocular conditions requiring ongoing therapy and/or monitoring must be discussed with the sponsor prior to enrollment. Additional protocol defined inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

HonorHealth Research InstituteScottsdale, Arizona
Florida Cancer SpecialistsSarasota, Florida
Massachusetts General HospitalBoston, Massachusetts
SCRI Oncology PartnersNashville, Tennessee
The University of Texas MD Anderson Cancer CenterHouston, Texas
START Mountain Cancer CenterSalt Lake City, Utah
Institution of Hunan Cancer HospitalChangsha, Hunan

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 1, 2026. Always confirm current availability with the study team.

View original record ↗